References
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, . National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123–32.
- Fox LP. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy. Oncology 2006; 20:26–34.
- Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol 2008;26:3460–2.
- Alexandrescu DT, Kauffman CL, Dasanu CA. Persistent hair growth during treatment with the EGFR inhibitor erlotinib. Dermatol Online J 2009;15:4.
- Márquez G, Herrera-Acosta E, Vidal I, Galvany L, Iglesias M, Umbert P. A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva). Int J Dermatol 2009;48:97–8.
- Montagut C, Grau JJ, Grimalt R, Codony J, Ferrando J, Albanell J. Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab. J Clin Oncol 2005;23:5273–5.
- Gryngarten M, Bedecarràs P, Ayuso S, Bergadà C, Campo S, Escobar ME. Clinical assessment and serum hormonal profile in prepubertal hypertrichosis. Horm Res 2000;54:20–5.
- Hansen LA, Alexander N, Hogan ME, Sundberg JP, Dlugosz A, Threadgill DW, . Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am J Pathol 1997;150:1959–75.
- Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, . Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527–37.